Evidence map›Paper›PMID 27822424›Full record

ArticleAmerican journal of cancer research2016

Nuclear TBLR1 as an ER corepressor promotes cell proliferation, migration and invasion in breast and ovarian cancer.

Xinyu Wu, Yang Zhan, Xin Li, Jianjun Wei, Larion Santiago, Garrett Daniels, Fangming Deng, Xuelin Zhong, Luis Chiriboga, Ross Basch and 4 more

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 4 countries.

Xinyu WuDepartment of Pathology, New York University School of Medicine New York, NY.
Yang ZhanStructural & Cellular Biology, Tulane University School of Medicine New Orleans, LA.
Xin LiBasic Science and Craniofacial Biology, New York University College of DentistryNew York, NY; Department of Urology, New York University School of MedicineNew York, NY; Department of NYU Cancer Institute, New York University School of MedicineNew York, NY.
Jianjun WeiDepartment of Pathology, Northwestern School of Medicine Chicago, IL.
Larion SantiagoDepartment of Pathology, New York University School of Medicine New York, NY.
Garrett DanielsDepartment of Pathology, New York University School of Medicine New York, NY.
Fangming DengDepartment of Pathology, New York University School of Medicine New York, NY.
Xuelin ZhongDepartment of Pathology, New York University School of Medicine New York, NY.
Luis ChiribogaDepartment of Pathology, New York University School of Medicine New York, NY.
Ross BaschDepartment of Pathology, New York University School of Medicine New York, NY.
Sheng XiongDepartment of Pathology, New York University School of Medicine New York, NY.
Yan DongStructural & Cellular Biology, Tulane University School of Medicine New Orleans, LA.
Xinmin ZhangDepartment of Pathology, Hofstra North Shore-LIJ School of Medicine Hempstead, New York, NY.
Peng LeeDepartment of Pathology, New York University School of MedicineNew York, NY; Department of Urology, New York University School of MedicineNew York, NY; Department of NYU Cancer Institute, New York University School of MedicineNew York, NY; Department of New York Harbor Healthcare System, New York University School of MedicineNew York, NY.
Shandong University of Political Science and Law · CNNew York University · USSupélec · FRTulane University · US

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1M
(PQA1) Novel epigenetic mechanism mediate metformin inhibition of prostate cancerR01CA180277 · NCI · NEW YORK UNIVERSITY · PI LI, XIN · 2013 to 2016
$1.1M
Sandy Recovery Ventana Medical Systems Discovery XTS10OD018338 · OD · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CHIRIBOGA, LUIS A · 2014 to 2014
$123k
NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA180277NIH HHS S10 OD018338
6 · The paper itself

Abstract

Estrogen receptors (ER) play important roles in the development and progression of breast and ovarian cancers. ERs mediate transcriptional regulation through interaction with cofactors and binding to response elements within the regulatory elements of target genes. Here, we examined the expression and function of TBLR1/TBL1XR1, a core component of NCoR (nuclear receptor corepressor) and SMRT (silencing mediator of retinoic acid and thyroid receptor) corepressor complexes, in breast and ovarian cancers. We found that although TBLR1 is present in both the nucleus and cytoplasm of normal and neoplastic breast and ovarian cells, it is expressed at significantly higher levels in the nucleus of malignant breast and ovarian cells compared to benign cells. TBLR1 functions as an ER corepressor to inhibit ER-mediated transcriptional activation in both breast and ovarian cell lines, but it has no effect on androgen receptor (AR) mediated transcriptional activation in these cells. Furthermore, ectopic expression of nuclear TBLR1 in breast and ovarian cancer cells stimulates cell proliferation. The increased cell proliferation by nuclear TBLR1 is through both ER-independent and ER-dependent mechanisms as evidenced by increased growth in hormone-free medium and estrogen medium, as well as reduced growth with ER knockdown by siRNA. Nuclear TBLR1 overexpression also increased migration and invasion in both breast and ovarian cancer cells. Determining the functional relationship between TBLR1 and ER may provide insights to develop novel treatment strategies and improve response to hormonal therapy in breast and ovarian cancers.

Indexed as

Breast cancerestrogen receptornuclear TBLR1ovarian cancerTBL1XR1

Identifiers

PMID27822424
PMCPMC5088298
OpenAlexW2565274046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.